You just read:

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

News provided by

AbbVie

28 Jul, 2017, 16:03 BST